RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a prominent biopharmaceutical company headquartered in Israel, focuses on the development and commercialisation of innovative therapies for gastrointestinal diseases and cancer. Founded in 2009, RedHill has made significant strides in the industry, particularly with its core products, which include advanced treatments that leverage unique mechanisms of action to address unmet medical needs. With a strong presence in both the Israeli and international markets, RedHill has established itself as a leader in the biopharma sector. The company’s commitment to research and development has led to notable achievements, including successful clinical trials and strategic partnerships that enhance its market position. RedHill Biopharma continues to push the boundaries of medical science, aiming to improve patient outcomes through its cutting-edge therapies.
DitchCarbon Score
How does RedHill Biopharma Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
RedHill Biopharma Ltd.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
RedHill Biopharma Ltd.'s reported carbon emissions
RedHill Biopharma Ltd., headquartered in Israel (IL), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that RedHill Biopharma Ltd. may still be in the early stages of developing a comprehensive climate strategy. As the biopharmaceutical industry increasingly prioritises sustainability, it is essential for companies like RedHill Biopharma Ltd. to establish clear climate commitments and reduction initiatives to align with industry standards and stakeholder expectations. Without specific emissions data or targets, the company may face challenges in demonstrating its commitment to reducing its carbon footprint and contributing to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
RedHill Biopharma Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
